| Literature DB >> 18844596 |
Andrew W Artenstein1, John D Grabenstein.
Abstract
Smallpox, eradicated as a cause of natural disease through an intensive global effort in the later part of the 20th Century, has resurfaced as a possible agent of bioterrorism. For this reason, there is renewed interest in smallpox vaccines. Live vaccinia virus, an orthopoxvirus related to smallpox, has a long and successful clinical track record as an effective smallpox vaccine; however, its use is associated with uncommon yet serious adverse events. This has led to a surge of recent research into newer-generation smallpox vaccines with improved safety profiles and retained efficacy. This article will review the history of smallpox vaccines, assess the status of newer-generation vaccines and examine the overall risk-versus-benefit profile of smallpox vaccination.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18844596 DOI: 10.1586/14760584.7.8.1225
Source DB: PubMed Journal: Expert Rev Vaccines ISSN: 1476-0584 Impact factor: 5.217